RxDoctor Payments Data

Pauline Soucy, APRN

Nurse Practitioner · Lowell, MANPI 1629673140

Payments from drug & device makers

$1,377in general payments, 2019–2025

Across 31 payments — averaging $44.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$333
  • Jazz Pharmaceuticals Inc.$137
  • Epizyme, Inc.$131
  • Gilead$129
  • E.r. Squibb & Sons, L.L.C.$112
  • EMD Serono, Inc.$109
  • plus $424 from 10 others

What the payments were for

  • Food & beverage$1,377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,377 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$51,892
Medicare patients
227
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide42$536,766
RevlimidLenalidomide25$483,557
PomalystPomalidomide22$480,000
TagrissoOsimertinib Mesylate24$403,441
NubeqaDarolutamide27$349,988
PromactaEltrombopag Olamine13$336,853
IbrancePalbociclib16$256,847
Abiraterone Acetate49$151,568
EliquisApixaban27$18,690
Anastrozole41$1,391
Acyclovir42$516
Prochlorperazine Maleate32$471
Gabapentin35$442
Potassium Chloride11$426
Dexamethasone26$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$36$483,55725 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$112$480,00022 claims
AstraZenecaTagrisso$48$403,44124 claims
BayerNubeqa$50$349,98827 claims
NovartisPromacta$22$336,85313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →